These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 1408133)

  • 1. Specific and complex interactions of murine p53 with DNA.
    Weissker SN; Müller BF; Homfeld A; Deppert W
    Oncogene; 1992 Oct; 7(10):1921-32. PubMed ID: 1408133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA binding properties of murine p53.
    Steinmeyer K; Deppert W
    Oncogene; 1988 Nov; 3(5):501-7. PubMed ID: 2978867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between the conformational phenotype of p53 and its subcellular location.
    Zerrahn J; Deppert W; Weidemann D; Patschinsky T; Richards F; Milner J
    Oncogene; 1992 Jul; 7(7):1371-81. PubMed ID: 1620550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutant p53: "gain of function" through perturbation of nuclear structure and function?
    Deppert W; Göhler T; Koga H; Kim E
    J Cell Biochem Suppl; 2000; Suppl 35():115-22. PubMed ID: 11389540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Partially transformed T3T3 cells express high levels of mutant p53 in the 'wild-type' immunoreactive form with defective oligomerization.
    Milner J; Chan YS; Medcalf EA; Wang Y; Eckhart W
    Oncogene; 1993 Jul; 8(7):2001-8. PubMed ID: 8510941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific binding of MAR/SAR DNA-elements by mutant p53.
    Müller BF; Paulsen D; Deppert W
    Oncogene; 1996 May; 12(9):1941-52. PubMed ID: 8649855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A PAb240+ conformation of wild type p53 binds DNA.
    McLure KG; Lee PW
    Oncogene; 1996 Sep; 13(6):1297-303. PubMed ID: 8808704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The DNA binding activity of wild type p53 is modulated by blocking its various antigenic epitopes.
    Wolkowicz R; Elkind NB; Ronen D; Rotter V
    Oncogene; 1995 Mar; 10(6):1167-74. PubMed ID: 7535417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of genomic DNA sequences bound by mutant p53 protein (Gly245-->Ser) in vivo.
    Koga H; Deppert W
    Oncogene; 2000 Aug; 19(36):4178-83. PubMed ID: 10962580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 binds the nuclear matrix in normal cells: binding involves the proline-rich domain of p53 and increases following genotoxic stress.
    Jiang M; Axe T; Holgate R; Rubbi CP; Okorokov AL; Mee T; Milner J
    Oncogene; 2001 Sep; 20(39):5449-58. PubMed ID: 11571642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of p53 transactivation through high-affinity binding sites.
    Chumakov AM; Miller CW; Chen DL; Koeffler HP
    Oncogene; 1993 Nov; 8(11):3005-11. PubMed ID: 8414502
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA-damage-inducible p53 activity in SV40-transformed cells.
    Hess RD; Brandner G
    Oncogene; 1997 Nov; 15(20):2501-4. PubMed ID: 9395246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines.
    Park DJ; Nakamura H; Chumakov AM; Said JW; Miller CW; Chen DL; Koeffler HP
    Oncogene; 1994 Jul; 9(7):1899-906. PubMed ID: 8208536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The N terminus of the murine p53 tumour suppressor is an independent regulatory domain affecting activation and thermostability.
    Hansen S; Lane DP; Midgley CA
    J Mol Biol; 1998 Jan; 275(4):575-88. PubMed ID: 9466932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 'Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain.
    Lányi A; Deb D; Seymour RC; Ludes-Meyers JH; Subler MA; Deb S
    Oncogene; 1998 Jun; 16(24):3169-76. PubMed ID: 9671396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcription factor binding sites in the matrix attachment region (MAR) of the chicken alpha-globin gene.
    Boulikas T
    J Cell Biochem; 1994 Aug; 55(4):513-29. PubMed ID: 7962181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural and kinetic analysis of p53-DNA complexes and comparison of human and murine p53.
    Hall AR; Milner J
    Oncogene; 1995 Feb; 10(3):561-7. PubMed ID: 7845681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Addition of fresh medium induces cell cycle and conformation changes in p53, a tumour suppressor protein.
    Milner J; Watson JV
    Oncogene; 1990 Nov; 5(11):1683-90. PubMed ID: 2176282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell cycle control by p53 in normal (3T3) and chemically transformed (Meth A) mouse cells. I. Regulation of p53 expression.
    Steinmeyer K; Maacke H; Deppert W
    Oncogene; 1990 Nov; 5(11):1691-9. PubMed ID: 2267135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The p53 tumor suppressor gene and gene product.
    Levine AJ
    Princess Takamatsu Symp; 1989; 20():221-30. PubMed ID: 2488233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.